Moreover, we found that upregulation of these proteins in EVs derived from the blood of a pilot cohort of breast cancer patients with metastatic ErbB2-positive breast cancer tends to correlate with trastuzumab sensitivity of patients’ tumors. Here, ERBB2 is linked to breast carcinoma.